Another study by Gutzman, found that idebenone had a greater improvement than tacrine in cognitive tests and more patients stopped taking tacrine (35). It is unclear whether treatment with coenzyme Q10 would compare to treatment with idebenone which is a synthetic drug available by prescription.
De Bustos, F et al found that co-enzyme Q10) levels were similar in Alzheimer’s patients, and patients with vascular dementia when compared to controls (36).
Coenzyme Q10 and Parkinson’s disease:
The response of daily oral application of 360 mg coenzyme Q10 (CoQ10) on 28 treated and stable Parkinson’s disease (PD) patients was examined for 4 weeks in this monocenter, parallel group, placebo controlled, double-blind trial. The two measures of interested included scored PD symptoms and visual function, measured with the Farnsworth-Munsell 100 Hue test (FMT). The Farnsworth Munsell 100 Hue Test tests the ability to discriminate between various shades of a given color. Compared to placebo, CoQ(10) supplementation provided a significant (p=0.01) mild symptomatic benefit on PD symptoms and a significantly (p=0.008) better improvement of FMT performance. In conclusion CoQ(10) supplementation resulted in a beneficial effect in PD patients. (23)